/MENS
MENS Stock - Jyong Biotech Ltd. Ordinary Shares
Healthcare|BiotechnologyNASDAQ
$3.17-4.65%
$0.15 (-4.65%) • Dec 19
38
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.12
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.0
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $3.49
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for MENS
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$3.14 – $3.21
TARGET (TP)$3.65
STOP LOSS$2.92
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta6.19
52W High$67.00
52W Low$2.60
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | $-120,000 | $-127,000 | $-122,000 | $-121,000 | N/A |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-2,056,000 | $-2,797,000 | $-2,829,000 | $-2,404,000 | $-2,446,000 |
| Net Income | $-3,019,000 | $-4,400,000 | $-6,630,000 | $-4,198,000 | $-1,916,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-0.04 | $-0.06 | $-0.09 | $-0.06 | $-0.03 |
Company Overview
Jyong Biotech Ltd. is a Taiwan-based biotech firm focused on developing and commercializing plant-derived drugs targeting urinary system diseases. The company operates through its subsidiaries—Health Ever Bio-Tech, Genvace, and others—working on drug candidates like MCS‑2 (for BPH) currently in Phase III, PCP (for prostate cancer) in Phase II, and IC in pre-clinical stages
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
MENSLoading earnings data...
Latest News
Jyong Biotech Reaffirms Compliance With Disclosure Obligations Under SEC Regulations, In Discussions With Certain Investment Funds For Share Sale
➖ NeutralBenzinga•Dec 19, 2025, 02:03 PM
Jyong Biotech Enters Into Non-Binding MOU With Vietnam‑Based Pharmaceutical Distribution Company To Evaluate Development And Commercialization Of MCS‑2 In Vietnam
📈 PositiveBenzinga•Dec 4, 2025, 01:38 PM
Jyong Biotech Signs MoU With South Korean Pharmaceutical Company To Review, Evaluate Licensing, Development Of Jyong Biotech's Plant-Derived New Drug MCS-2
📈 PositiveBenzinga•Nov 24, 2025, 01:35 PM
Jyong Biotech shares are trading higher after the company announced it has completed the statistical analysis of the primary efficacy endpoints in its current phase 2 clinical study of MCS-8 in Taiwan.
📈 PositiveBenzinga•Nov 20, 2025, 03:36 PM
Jyong Biotech Completes Statistical Analysis Of Primary Efficacy Endpoints In Ongoing Phase II Clinical Trial Of MCS-8 Conducted In Taiwan
➖ NeutralBenzinga•Nov 20, 2025, 01:38 PM
Jyong Biotech shares are trading higher after the company announces completion of patient enrollment of over 700 subjects in phase II clinical trial of MCS‑8 for prostate cancer prevention.
📈 PositiveBenzinga•Sep 16, 2025, 05:47 PM
Frequently Asked Questions about MENS
What is MENS's current stock price?
Jyong Biotech Ltd. Ordinary Shares (MENS) is currently trading at $3.17 per share. The stock has moved -4.65% today.
What is the analyst price target for MENS?
No analyst price targets are currently available for this stock.
What sector is Jyong Biotech Ltd. Ordinary Shares in?
Jyong Biotech Ltd. Ordinary Shares operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is MENS's market cap?
Jyong Biotech Ltd. Ordinary Shares has a market capitalization of $0.24 billion, making it a small-cap company.
Does MENS pay dividends?
No, Jyong Biotech Ltd. Ordinary Shares does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAAPG
ASCENTAGE PHARMA GROUP INTERNATIONAL
$29.31
Mkt Cap: $2.7B
APGE
Apogee Therapeutics, Inc.
$78.54
Mkt Cap: $4.3B
CELC
Celcuity Inc.
$101.16
Mkt Cap: $4.7B
CGON
CG Oncology, Inc. Common stock
$39.03
Mkt Cap: $2.9B
CNTA
Centessa Pharmaceuticals plc
$24.85
Mkt Cap: $3.3B
DYN
Dyne Therapeutics, Inc.
$19.85
Mkt Cap: $2.8B
LEGN
Legend Biotech Corporation
$21.92
Mkt Cap: $2.0B
RARE
Ultragenyx Pharmaceutical Inc.
$33.50
Mkt Cap: $3.2B
TVTX
Travere Therapeutics, Inc.
$34.51
Mkt Cap: $3.1B
XENE
Xenon Pharmaceuticals Inc.
$44.10
Mkt Cap: $3.4B
Explore stocks similar to MENS for comparison